Hemostasis Today

August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Mital Jhaveri: Anticoagulation in Advanced CKD – Why Individualized Decisions Matter
Aug 27, 2026, 13:20

Mital Jhaveri: Anticoagulation in Advanced CKD – Why Individualized Decisions Matter

Mital Jhaveri, Clinical Anticoagulation, Heart Failure Pharmacist at NYC HHC Queens Hospital Center, shared a post on LinkedIn about a recent article by Kathrine Parker et al., published in BMC Nephrology Journals, adding:

Anticoagulation in advanced kidney disease: when both clotting and bleeding risk are high, what is the right choice?

A newly published 2026 guideline highlights a challenge we face frequently in practice: patients with advanced CKD have increased risks of stroke, systemic embolism, and bleeding – yet they have historically been excluded from many major anticoagulation trials.

One particularly striking point: major DOAC trials largely excluded patients with CrCl less than 30 mL/min, leaving us with limited high-quality evidence precisely where thrombotic and bleeding risks are both high.

As a pharmacist working in anticoagulation, this reinforces that anticoagulation is never simply about choosing a drug and dose.

Renal function, bleeding risk, stroke risk, monitoring, and the individual patient all matter.

The best anticoagulation decision is an individualized one.”

Title: Anticoagulation for atrial fibrillation in adults with advanced kidney disease: UK kidney association clinical practice guideline

Authors: Kathrine Parker, Albert Power, Richard Buka, Mark Davies, Maria A. Gauci, Alan Hancock, John Hartemink, Anneka Mitchell, Honey Thomas, Jung Yin Tsang, Isaac Tseng, Andrew Turley, Gregory Y. H.

Mital Jhaveri

Stay updated on all scientific advances with Hemostasis Today.